Conference call to report on Phase3 OnTarget Trial results for its Cancer Supportive Care Drug Crofelemer to be held on July 23 at 8:30 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Biotech Alert: Searches spiking for these stocks today
- Jaguar Health announces issuance of European, Australian patents
- Jaguar Health regains compliance with Nasdaq’s bid price requirement
- Jaguar Health Stockholders Approve Key Proposals at 2024 Meeting
- Jaguar Health to report Phase 3 OnTarget trial results on or before July 23